Predictive Signature of Benralizumab Response

This study uses biological samples to identify markers in the blood that can predict which patients with severe asthma will respond well to benralizumab — a biologic injection that targets a white blood cell type (eosinophils) that drives asthma inflammation. **You may be eligible if...** - You are between 18 and 75 years old - You have severe asthma requiring high doses of inhaled steroids plus additional medications, and your asthma is still poorly controlled or worsens when medications are reduced - You have had at least 3 asthma flare-ups in the past year - Your blood shows signs of eosinophilic (allergy-related) inflammation - You have documented reversibility of airflow obstruction on breathing tests **You may NOT be eligible if...** - Your breathing problems are due to a different condition (such as vocal cord dysfunction or sleep apnea) - You have another condition causing eosinophilia - You are pregnant or breastfeeding - You have severe uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.